<p>瑞銀資產管理（UBS AM），瑞銀資產管理美洲有限公司（UBS ASSET MANAGEMENT AMERICAS LLC）的一家獨立業務單位，在最近向證券交易委員會（SEC）提交的 13F 文件中披露，在第四季度增持了輝瑞公司（Pfizer Inc.，NYSE:PFE - 免費報告）4.4% 的股份。該基金在此期間額外收購了 1,517,551 股後，持有該生物製藥公司 35,713,035 股股票。瑞銀資產管理（UBS AM）在最近一個季度末持有輝瑞約 0.63% 的股份，價值 889,255,000 美元。</p>
<ul>
<li>專利懸崖掠奪者：GSK 以 106 億美元收購 Nuvalent</li>
</ul>
<p>其他大型投資者也買賣了該公司的股票。Horizon Financial Services LLC 在第四季度將其在輝瑞的持倉增加了 174.8%。Horizon Financial Services LLC 目前持有輝瑞 1,014 股股票，價值 25,000 美元，此前在上個季度額外購買了 645 股。Godfrey Financial Associates Inc.在第四季度以 26,000 美元的價格新建了輝瑞的持倉。YANKCOM Partnership 在第四季度以 28,000 美元的價格新建了輝瑞的持倉。HFM Investment Advisors LLC 在第四季度將其在輝瑞的持倉增加了 61.0%。HFM Investment Advisors LLC 目前持有輝瑞 1,127 股股票，價值 28,000 美元，此前在上個季度額外購買了 427 股。最後，Darwin Wealth Management LLC 在第二季度以 32,000 美元的價格新建了輝瑞的持倉。目前 68.36% 的股票由機構投資者持有。</p>
<h2>輝瑞新聞匯總</h2>
<p>以下是本週影響輝瑞的主要新聞：</p>
<ul>
<li>積極情緒：輝瑞的新減肥數據被視為對其肥胖業務的鼓舞，可能改善其管線的競爭案例，並幫助未來增長的情緒。文章標題</li>
<li>積極情緒：輝瑞針對 HYMPAVZI 的美國標籤擴展增加了對血友病業務的樂觀情緒，擴大了可服務的患者羣體，這可能支持未來的特種藥物銷售。文章標題</li>
<li>積極情緒：RBC 最近將輝瑞評級上調至行業表現，稱估值已重置，風險回報特徵在管線催化劑之前看起來更為平衡。文章標題</li>
<li>積極情緒：一些近期文章認為輝瑞的 Seagen 腫瘤學平台和新收購的肥胖資產可能有助於抵消專利到期和後 COVID 的收入壓力，支持長期反轉的論點。文章標題</li>
<li>中性情緒：分析師目前對輝瑞的平均評級為持有，表明市場在更多管線和商業執行證明之前，看到有限的短期上行空間。文章標題</li>
<li>消極情緒：看跌評論繼續強調輝瑞的股息收益率作為對現金流、債務和公司支持股息和再投資能力的潛在擔憂的標誌。文章標題</li>
</ul>
<h2>華爾街分析師觀點</h2>
<ul>
<li>應對大型製藥專利懸崖的兩種方式</li>
</ul>
<p>多位研究分析師對輝瑞股票發表了評論。Zacks Research 在 2 月 24 日的研究報告中將輝瑞的評級從 “強烈賣出” 上調至 “持有”。Wolfe Research 在 5 月 14 日的研究報告中重申了 “表現不佳” 的評級，並對輝瑞的股票設定了 26.00 美元的目標價。美國銀行在 4 月 9 日的研究報告中將輝瑞的目標價從 27.00 美元下調至 26.00 美元，並對該股票設定了 “中性” 評級。瑞銀集團在 5 月 27 日的研究報告中重申了 “中性” 評級，並對輝瑞的股票設定了 27.00 美元的目標價。最後，花旗集團在 4 月 29 日的研究報告中將輝瑞的目標價從 26.00 美元上調至 27.00 美元，並給予公司 “中性” 評級。一位投資分析師對該股票給予了強烈買入評級，五位給予買入評級，十二位給予持有評級，兩位給予賣出評級。根據 MarketBeat 的數據，該股票目前的平均評級為 “持有”，共識目標價為 28.82 美元。</p>
<p><strong>閲讀我們最新的輝瑞股票分析</strong></p>
<h2>輝瑞股票表現</h2>
<ul>
<li>5 只高收益股票，保護您的投資組合免受風暴影響</li>
</ul>
<p>輝瑞股票週五開盤價為 26.19 美元。該公司的市值為 1492.6 億美元，市盈率為 19.99，貝塔係數為 0.34。輝瑞公司 12 個月低點為 23.11 美元，12 個月高點為 28.75 美元。該公司的流動比率為 1.25，速動比率為 0.94，債務與股本比率為 0.67。該股票的 50 日簡單移動平均線為 26.43 美元，200 日簡單移動平均線為 26.32 美元。</p>
<p>輝瑞（NYSE:PFE - 獲取免費報告）最近在 5 月 5 日發佈了季度財報。該生物製藥公司報告季度每股收益（EPS）為 0.75 美元，超出市場共識預期的 0.72 美元，超出 0.03 美元。該業務的季度收入為 144.5 億美元，而市場共識預期為 138.4 億美元。輝瑞的股本回報率為 19.44%，淨利潤率為 11.83%。該公司的收入較去年同期增長了 5.4%。去年同期，該業務的每股收益為 0.92 美元。輝瑞已將其 2026 財年的指導目標設定為 2.800-3.000 每股收益。研究分析師平均預測輝瑞公司今年的每股收益為 2.99 美元。</p>
<h2>輝瑞宣佈分紅</h2>
<p>該公司最近還披露了季度分紅，已於 6 月 12 日支付。5 月 8 日的登記投資者每股獲得 0.43 美元的分紅。這代表着每年 1.72 美元的分紅，收益率為 6.6%。該分紅的除息日期為 5 月 8 日。輝瑞的分紅支付比率（DPR）目前為 131.30%。</p>
<h2>輝瑞公司簡介</h2>
<p>（免費報告）</p>
<p>輝瑞公司（Pfizer Inc）在紐約證券交易所上市，股票代碼為 PFE，是一家總部位於紐約市的跨國生物製藥公司。公司成立於 1849 年，由查爾斯·輝瑞（Charles Pfizer）和查爾斯·厄哈特（Charles Erhart）創立，專注於人類健康的藥物和疫苗的研究、開發、生產和商業化。其業務涵蓋發現研究、臨牀開發、監管事務、製造和全球商業分銷，涉及多個治療領域。</p>
<p>輝瑞的產品組合和研發管線涵蓋腫瘤學、免疫學、心臟病學、內分泌學、罕見疾病、醫院急救和抗感染藥物，以及一個可觀的疫苗業務。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們認為比輝瑞更好的股票</li>
<li>SpaceX 敲響開盤鍾，打破所有記錄</li>
<li>Adobe 股票剛剛變便宜——華爾街是否忽視了這個故事？</li>
<li>三隻低於 50 美元的分紅股票，支付你等待通脹的時間</li>
<li>127 吉瓦的問題：為什麼人工智能需要自己的電力</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在輝瑞嗎？</h2>
<p>在考慮輝瑞之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而輝瑞並不在名單上。</p>
<p>雖然輝瑞目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

輝瑞

瑞銀集團

<p>瑞銀資產管理在第四季度將其輝瑞的持股增加了 4.4%，收購了 1,517,551 股，總持股達到 3570 萬股，價值約為 8.893 億美元。其他投資者如 Horizon Financial 也增加了持倉。分析師的情緒仍然不一；Zacks 將輝瑞評級上調至 “持有”，而其他分析師則維持中性或表現不佳的評級，目標價在 26 至 27 美元之間。該股票目前交易價格接近 26.19 美元，市場共識目標價為 28.82 美元</p>

<p>UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 4.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 35,713,035 shares of the biopharmaceutical company's stock after acquiring an additional 1,517,551 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.63% of Pfizer worth $889,255,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>瑞銀資產管理（UBS AM），瑞銀資產管理美洲有限公司（UBS ASSET MANAGEMENT AMERICAS LLC）的一家獨立業務單位，在最近向證券交易委員會（SEC）提交的 13F 文件中披露，在第四季度增持了輝瑞公司（Pfizer Inc.，NYSE:PFE - 免費報告）4.4% 的股份。該基金在此期間額外收購了 1,517,551 股後，持有該生物製藥公司 35,713,035 股股票。瑞銀資產管理（UBS AM）在最近一個季度末持有輝瑞約 0.63% 的股份，價值 889,255,000 美元。</p>
</div><ul>
<li>Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion</li>
</ul>
<div class="lb-trans"><ul>
<li>專利懸崖掠奪者：GSK 以 106 億美元收購 Nuvalent</li>
</ul>
</div><p>Other large investors have also bought and sold shares of the company. Horizon Financial Services LLC boosted its position in Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 645 shares during the last quarter. Godfrey Financial Associates Inc. bought a new position in Pfizer in the 4th quarter valued at $26,000. YANKCOM Partnership bought a new position in Pfizer in the 4th quarter valued at $28,000. HFM Investment Advisors LLC boosted its position in Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 427 shares during the last quarter. Finally, Darwin Wealth Management LLC bought a new position in Pfizer in the 2nd quarter valued at $32,000. 68.36% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他大型投資者也買賣了該公司的股票。Horizon Financial Services LLC 在第四季度將其在輝瑞的持倉增加了 174.8%。Horizon Financial Services LLC 目前持有輝瑞 1,014 股股票，價值 25,000 美元，此前在上個季度額外購買了 645 股。Godfrey Financial Associates Inc.在第四季度以 26,000 美元的價格新建了輝瑞的持倉。YANKCOM Partnership 在第四季度以 28,000 美元的價格新建了輝瑞的持倉。HFM Investment Advisors LLC 在第四季度將其在輝瑞的持倉增加了 61.0%。HFM Investment Advisors LLC 目前持有輝瑞 1,127 股股票，價值 28,000 美元，此前在上個季度額外購買了 427 股。最後，Darwin Wealth Management LLC 在第二季度以 32,000 美元的價格新建了輝瑞的持倉。目前 68.36% 的股票由機構投資者持有。</p>
</div><h2>Pfizer News Roundup</h2>
<div class="lb-trans"><h2>輝瑞新聞匯總</h2>
</div><p>Here are the key news stories impacting Pfizer this week:</p>
<div class="lb-trans"><p>以下是本週影響輝瑞的主要新聞：</p>
</div><ul>
<li>Positive Sentiment: Pfizer’s new weight-loss data is being viewed as encouraging for its obesity franchise, potentially improving the competitive case for its pipeline and helping sentiment around future growth. Article Title</li>
<li>Positive Sentiment: Pfizer’s expanded U.S. label for HYMPAVZI is adding to optimism around the hemophilia business by widening the addressable patient pool, which may support future specialty-drug sales. Article Title</li>
<li>Positive Sentiment: RBC recently upgraded Pfizer to Sector Perform, saying the valuation has reset and the risk-reward profile looks more balanced ahead of pipeline catalysts. Article Title</li>
<li>Positive Sentiment: Some recent articles argue Pfizer’s Seagen oncology platform and newly acquired obesity assets could help offset patent-expiry and post-COVID revenue pressure, supporting a long-term turnaround thesis. Article Title</li>
<li>Neutral Sentiment: Analysts currently rate Pfizer around Hold on average, suggesting the market sees limited near-term upside until more pipeline and commercial execution proves out. Article Title</li>
<li>Negative Sentiment: Bearish commentary continues to highlight Pfizer’s dividend yield as a sign of underlying concern about cash flow, debt, and the company’s ability to support both payouts and reinvestment. Article Title</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：輝瑞的新減肥數據被視為對其肥胖業務的鼓舞，可能改善其管線的競爭案例，並幫助未來增長的情緒。文章標題</li>
<li>積極情緒：輝瑞針對 HYMPAVZI 的美國標籤擴展增加了對血友病業務的樂觀情緒，擴大了可服務的患者羣體，這可能支持未來的特種藥物銷售。文章標題</li>
<li>積極情緒：RBC 最近將輝瑞評級上調至行業表現，稱估值已重置，風險回報特徵在管線催化劑之前看起來更為平衡。文章標題</li>
<li>積極情緒：一些近期文章認為輝瑞的 Seagen 腫瘤學平台和新收購的肥胖資產可能有助於抵消專利到期和後 COVID 的收入壓力，支持長期反轉的論點。文章標題</li>
<li>中性情緒：分析師目前對輝瑞的平均評級為持有，表明市場在更多管線和商業執行證明之前，看到有限的短期上行空間。文章標題</li>
<li>消極情緒：看跌評論繼續強調輝瑞的股息收益率作為對現金流、債務和公司支持股息和再投資能力的潛在擔憂的標誌。文章標題</li>
</ul>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><ul>
<li>2 Ways to Play the Big Pharma Patent Cliff</li>
</ul>
<div class="lb-trans"><ul>
<li>應對大型製藥專利懸崖的兩種方式</li>
</ul>
</div><p>A number of research analysts have commented on PFE shares. Zacks Research upgraded Pfizer from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, February 24th. Wolfe Research reissued an &#34;underperform&#34; rating and issued a $26.00 price target on shares of Pfizer in a research note on Thursday, May 14th. Bank of America cut their price target on Pfizer from $27.00 to $26.00 and set a &#34;neutral&#34; rating on the stock in a research note on Thursday, April 9th. UBS Group reissued a &#34;neutral&#34; rating and issued a $27.00 price target on shares of Pfizer in a research note on Wednesday, May 27th. Finally, Citigroup increased their price target on Pfizer from $26.00 to $27.00 and gave the company a &#34;neutral&#34; rating in a research note on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of &#34;Hold&#34; and a consensus target price of $28.82.</p>
<div class="lb-trans"><p>多位研究分析師對輝瑞股票發表了評論。Zacks Research 在 2 月 24 日的研究報告中將輝瑞的評級從 “強烈賣出” 上調至 “持有”。Wolfe Research 在 5 月 14 日的研究報告中重申了 “表現不佳” 的評級，並對輝瑞的股票設定了 26.00 美元的目標價。美國銀行在 4 月 9 日的研究報告中將輝瑞的目標價從 27.00 美元下調至 26.00 美元，並對該股票設定了 “中性” 評級。瑞銀集團在 5 月 27 日的研究報告中重申了 “中性” 評級，並對輝瑞的股票設定了 27.00 美元的目標價。最後，花旗集團在 4 月 29 日的研究報告中將輝瑞的目標價從 26.00 美元上調至 27.00 美元，並給予公司 “中性” 評級。一位投資分析師對該股票給予了強烈買入評級，五位給予買入評級，十二位給予持有評級，兩位給予賣出評級。根據 MarketBeat 的數據，該股票目前的平均評級為 “持有”，共識目標價為 28.82 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on Pfizer</strong></p>
<div class="lb-trans"><p><strong>閲讀我們最新的輝瑞股票分析</strong></p>
</div><h2>Pfizer Stock Performance</h2>
<div class="lb-trans"><h2>輝瑞股票表現</h2>
</div><ul>
<li>5 High-Yield Stocks to Shield Your Portfolio From the Storm</li>
</ul>
<div class="lb-trans"><ul>
<li>5 只高收益股票，保護您的投資組合免受風暴影響</li>
</ul>
</div><p>Shares of Pfizer stock opened at $26.19 on Friday. The company has a market capitalization of $149.26 billion, a PE ratio of 19.99 and a beta of 0.34. Pfizer Inc. has a 12 month low of $23.11 and a 12 month high of $28.75. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The stock's fifty day simple moving average is $26.43 and its 200 day simple moving average is $26.32.</p>
<div class="lb-trans"><p>輝瑞股票週五開盤價為 26.19 美元。該公司的市值為 1492.6 億美元，市盈率為 19.99，貝塔係數為 0.34。輝瑞公司 12 個月低點為 23.11 美元，12 個月高點為 28.75 美元。該公司的流動比率為 1.25，速動比率為 0.94，債務與股本比率為 0.67。該股票的 50 日簡單移動平均線為 26.43 美元，200 日簡單移動平均線為 26.32 美元。</p>
</div><p>Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm's revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts predict that Pfizer Inc. will post 2.99 EPS for the current year.</p>
<div class="lb-trans"><p>輝瑞（NYSE:PFE - 獲取免費報告）最近在 5 月 5 日發佈了季度財報。該生物製藥公司報告季度每股收益（EPS）為 0.75 美元，超出市場共識預期的 0.72 美元，超出 0.03 美元。該業務的季度收入為 144.5 億美元，而市場共識預期為 138.4 億美元。輝瑞的股本回報率為 19.44%，淨利潤率為 11.83%。該公司的收入較去年同期增長了 5.4%。去年同期，該業務的每股收益為 0.92 美元。輝瑞已將其 2026 財年的指導目標設定為 2.800-3.000 每股收益。研究分析師平均預測輝瑞公司今年的每股收益為 2.99 美元。</p>
</div><h2>Pfizer Announces Dividend</h2>
<div class="lb-trans"><h2>輝瑞宣佈分紅</h2>
</div><p>The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 12th. Investors of record on Friday, May 8th were paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.6%. The ex-dividend date of this dividend was Friday, May 8th. Pfizer's dividend payout ratio (DPR) is presently 131.30%.</p>
<div class="lb-trans"><p>該公司最近還披露了季度分紅，已於 6 月 12 日支付。5 月 8 日的登記投資者每股獲得 0.43 美元的分紅。這代表着每年 1.72 美元的分紅，收益率為 6.6%。該分紅的除息日期為 5 月 8 日。輝瑞的分紅支付比率（DPR）目前為 131.30%。</p>
</div><h2>Pfizer Company Profile</h2>
<div class="lb-trans"><h2>輝瑞公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.</p>
<div class="lb-trans"><p>輝瑞公司（Pfizer Inc）在紐約證券交易所上市，股票代碼為 PFE，是一家總部位於紐約市的跨國生物製藥公司。公司成立於 1849 年，由查爾斯·輝瑞（Charles Pfizer）和查爾斯·厄哈特（Charles Erhart）創立，專注於人類健康的藥物和疫苗的研究、開發、生產和商業化。其業務涵蓋發現研究、臨牀開發、監管事務、製造和全球商業分銷，涉及多個治療領域。</p>
</div><p>Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.</p>
<div class="lb-trans"><p>輝瑞的產品組合和研發管線涵蓋腫瘤學、免疫學、心臟病學、內分泌學、罕見疾病、醫院急救和抗感染藥物，以及一個可觀的疫苗業務。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Pfizer</li>
<li>SpaceX Rings the Bell and Shatters Every Record</li>
<li>Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?</li>
<li>3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation</li>
<li>The 127-Gigawatt Problem: Why AI Needs Its Own Power</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比輝瑞更好的股票</li>
<li>SpaceX 敲響開盤鍾，打破所有記錄</li>
<li>Adobe 股票剛剛變便宜——華爾街是否忽視了這個故事？</li>
<li>三隻低於 50 美元的分紅股票，支付你等待通脹的時間</li>
<li>127 吉瓦的問題：為什麼人工智能需要自己的電力</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=PFE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Pfizer Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在輝瑞嗎？</h2>
</div><p>Before you consider Pfizer, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮輝瑞之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而輝瑞並不在名單上。</p>
</div><p>While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然輝瑞目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 1,517,551 Shares of Pfizer Inc. $PFE

- UBS AM 增持 Pfizer 股票 4.4%，持股達 3571 萬股，市值 8.89 億美元。  
- Horizon Financial Services 增持 174.8%，現持有 1014 股，市值 2.5 萬美元。  
- Pfizer 第四季度營收增 5.4%，每股收益 0.75 美元，超過預期。

Market Beat

葛蘭素史克

Nuvalent

加拿大皇家銀行

美國銀行

花旗

GSK plc Sponsored ADR

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

CITIGROUP INC 6.250 NON CUM SER II PFD WI

瑞銀資產管理美洲有限責任公司（UBS ASSET MANAGEMENT AMERICAS LLC）旗下的獨立業務單元 UBS AM 收購了輝瑞公司（Pfizer Inc.）1,517,551 股股票